HIV/AIDS Treatment Trends and Progress: Where Do We Stand Today?
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Address: Suite 2 Building 4 Ruimsig Office Estate, Hole in One Avenue, Ruimsig, 1724 Roodepoort, Gauteng, South Africa
Tel: +27-11-9582168
Web: http://www.tevapharm.com/Pages/default.aspx
Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence.
Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 47,000 employees worldwide.
Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence.
Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API).
For over a century, Teva has maintained a distinct competitive edge through:
High quality offerings
Focus on customers and patients
Balanced product portfolio (both generic and innovative)
Integration of pharmaceutical and API activities
Combination of global operations with local customer responsiveness
Established international presence through a tailored network of worldwide subsidiaries
Teva aims to be the first to introduce the highest quality standards and the most competitive prices.
Teva’s branded products make a significant difference in people’s lives. We leverage our large-scale operations, scientific resources and global leadership to develop and produce drugs that are tailored to address patients’ needs.
Only the highest quality standards are implemented to ensure our customers’ wellbeing. As our branded business expands, we continue to explore new areas and exciting platforms, in pursuit of new products that can enhance your quality of life.
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
